50461-51-3

Usage

Chemical structure

Tetrahydrobipyridine compound

Pharmacological activity

Potential as a therapeutic agent for various conditions

Central nervous system

Acts as a depressant

Potential therapeutic applications

Addiction, anxiety, and pain management

Mechanism of action

Interacts with the brain's GABA receptors

Effects

Sedative and anxiolytic (anxiety-reducing) properties

Neurological disorders

Studied for potential treatment of Parkinson's disease and epilepsy

Ongoing research

Continued investigation into its therapeutic applications and potential benefits
These properties and contents are based on the information provided and highlight the compound's potential uses and areas of study.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 90606-75-0 4'-Hydroxy-3',4',5',6'-tetrahydro-2'H-[2,4']bipyridinyl-1'-carboxylic acid tert-butyl ester 
• 41979-39-9 4-piperidone hydrochloride 
• 109-04-6 2-bromo-pyridine 
• 90606-77-2 3',6'-dihydro-2'H-[2,4']bipyridinyl-1'-carboxylic acid tert-butyl ester 

Downstream Products

• 182415-09-4 Piclozotan 
• 1197901-70-4 (2R,3R)-2-(2,4-difluorophenyl)-3-(3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol 
• 30532-37-7 4-(2-pyridinyl)piperidine 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

Aryl-tetrahydropyridine derivatives were prepared and their PPARα/γ dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPARα/γ dual agonist with an EC50 of 1.73 and 0.64 μM in hPPARα and γ, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties.

Adrenoceptor and Tetrabenazine Antagonism Activities of Some Pyridinyltetrahydropyridines

A series of pyridinyltetrahydropyridine derivatives was synthesized and evaluated as adrenoceptor and tetrabenazine antagonists. 4-(3-Fluoro-2-pyridinyl)-1,2,5,6-tetrahydropyridine proved to be the most potent and selective α2-adrenoceptor antagonist of the series as measured in vitro by displacement of 3H>clonidine and 3H>prazosin from membrane binding sites of calf cerebral cortex and by antagonism of the effects of clonidine and methoxamine in the rat isolated, field-stimulated vas deferens.In addition, this compound, and the corresponding desfluoro derivative, blocked tetrabenazine-induced ptosis in the mouse.